Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of the Paperwork Reduction Act of the Paperwork

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	PCT/EP2004/010129
Filing Date	9 September 2004
First Named Inventor	Christopher Norbert JOHNSON
Title	NOVEL COMPOUNDS
Art Unit	
Examiner Name	
Attorney Docket Number	PB60501

I hereby appoint:				
Practitioners associated with the Customer Numbers. 20462				
Or				
☐ Practitioner(s) named below:				
Name	Reg	istration Number		
As my/our attorney(s) or agent(s) to prosecute the application	on identified above, and to transact a	all business in the		
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.				
Officed States I atom and Tradomark Office confected therewith.				
Please recognize or change the correspondence address for the above-identified application to:				
☐ The address associated with the above-mentioned Custo	• •			
Or				
The address associated with Customer Number 20462				
Or				
☐ Firm or Individual Name:				
Address:				
Address:				
City:	State:	Zip:		
Country:				
Telephone:	Fax:			
I am the:				
Applicant/Inventor:				
Assignee or record of the entire interest. See 37 CFR 3.71.				
Statement under 37 (CFR) 3.73(b) is enclosed. (Form PTO/SB/96)				
Signature: Signat				
1 120 00 1	elephone: +44 20 8047 4414			
Title and Company: Attorney and Authorised Official, Glaxo Group Limited				
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.				
Submit multiple forms if more than one signature is required, see below*.				
□ *Total of: forms are submitted.				

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

A10581-40

1AP20 Resided for 10 Mar 2006

PTO/SB/81 (06-04) Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to respond to a collection of information unless it displays a valid OMB control number to a collection of information unless it displays a valid OMB control number to a collection of information unless it displays a valid OMB control number to a collection of information unless it displays a valid OMB control number to a collection of information unless it displays a valid OMB control number to a collection of information unless it displays a collection of information unless it displays a collection of information unless it displays a collection of information unl

STATEMENT UNDER 37 CRF 3.73(b)		
Applicant/Patent Owner: Glaxo Group Limited		
International Application No./Patent No.: PCT/EP2004/010129 Filed/Issue Date: 9 September 2004		
Entitled: NOVEL COMPOUNDS		
Glaxo Group Limited, a corporation, states that it is:		
1. the assignee of the entire right, title, and interest; or		
2. \square an assignee of less than the entire right, title and interest.		
The extent (by percentage) of its ownership interest is% in the patent application/patent identified above		
by virtue of either;		
A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was		
recorded in the United States Patent and Trademark Office at Reel, Frame, or for which		
copy thereof is attached.		
OR		
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee		
as shown below:		
From: To: The document was recorded in the United States Patent and Trademark Office at		
The document was recorded in the United States Patent and Trademark Utilice at		
Reel , Frame , or for which a copy thereof is attached. 2. From: To: The document was recorded in the United States Patent and Trademark Office at		
Z. From: 10: 10: The decument was recorded in the United States Potent and Trademark Office at		
Pael Frame or for which a copy thereof is attached		
Reel , Frame , or for which a copy thereof is attached. 3. From: To: , or for which a copy thereof is attached.		
The document was recorded in the United States Patent and Trademark Office at		
Reel, Frame, or for which a copy thereof is attached.		
[] Additional documents in the chain of title are listed on a supplemental sheet.		
[X] Copies of assignments or other documents in the chain of title are attached.		
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment		
Division in accordance with 37 CRF Part 3, if the assignment is to be recorded in the records of the USPTO.		
See MPEP 302.08]		
The undersigned (whose hit supplied below) is authorized to act on behalf of the assignee.		
2 0 JAN 2005		
2 0 JAN 2003		
Signature 9 Date		
Peter John GIDDINGS +44 20 8047 4414		
Printed or Typed Name Telephone Number		
Attorney and Authorised Official		
Title		

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ASSIGNMENT

WHEREAS I/WE, Christopher Norbert JOHNSON and David R WITTY of Harlow, Essex, GB (hereinafter called "the inventor(s)") have invented or discovered "NOVEL COMPOUNDS" (hereinafter called "the invention") for which a patent application no. 0321473.1 was filed on 12 September 2003 in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT/EP2004/010129 filed 9 Sepember 2004)

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely GLAXOSMITHKLINE SERVICES UNLIMITED a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

WHEREAS GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED, a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from GLAXOSMITHKLINE SERVICES UNLIMITED the whole right, title and interest in and to the invention and the application, and

GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED have authorised and requested my/our making the application, and

WHEREAS GLAXO GROUP LIMITED a company organised and existing under and by virtue of the laws of England and Wales and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring from GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED the whole right, title and interest in

and to the invention and the application in respect of the United States of America:

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by GLAXOSMITHKLINE SERVICES **UNLIMITED** of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to GLAXOSMITHKLINE SERVICES UNLIMITED. GLAXOSMITHKLINE SERVICES UNLIMITED in turn hereby assigns and transfers to GLAXOSMITHKLINE RESEARCH AND **DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED in turn hereby assigns and transfers to GLAXO GROUP LIMITED its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and GLAXOSMITHKLINE RESEARCH SERVICES UNLIMITED and GLAXOSMITHKLINE **DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to GLAXO GROUP LIMITED.

AND GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in GLAXO GROUP

LIMITED, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IN WITNESS whereof and with effect from 12 September 2003 the inventor(s) and Peter John GIDDINGS as Attorney of both GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED by virtue of Powers of Attorney granted by GLAXOSMITHKLINE SERVICES UNLIMITED and GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED respectively have hereunto set their respective hands.

SIGNED by Christopher Norbert JOHN	NSON: Chinotopher Verbeiter
Date: 6th December 2004	
SIGNED by David R WITTY:	David of Welts
Date: 2nd December 2004	
	IGS as the Attorney of each o
GLAXOSMITHKLINE SERVICES L RESEARCH AND DEVELOPMENT LIN	INLIMITED and GLAXOSMITHKLINE IITED:
	1 9 JAN 2005 Date: